Is AbbVie (ABBV) overvalued or fairly valued?

MarketChacha shows AbbVie's valuation in context — a trailing P/E of about 79.9, a forward P/E of about 17.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does AbbVie's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (4.54×) from reported figures — education, not a rating.

What is AbbVie's revenue?

AbbVie reported revenue of $61.2B for FY2025, with net profit of $4.2B, per official filings.

What is the share price of AbbVie (ABBV)?

AbbVie last traded at $282.68 (-1.0% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

AbbVie

ABBV · NYSE · Pharma · United States

Snapshot

TickerABBV

ExchangeNYSE

SectorPharma

IndustryDrug Manufacturers - General

CountryUnited States

Employees57,000

HeadquartersNorth Chicago, United States

Websitewww.abbvie.com

Filings tracked22

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Who owns it

Insiders0.1%
Institutions77.3%
Public & other22.6%

5,262 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.46%
Vanguard Capital Management LLC6.53%
State Street Corporation4.67%
Vanguard Portfolio Management LLC2.74%
JPMORGAN CHASE & CO2.71%
Geode Capital Management, LLC2.66%
Morgan Stanley2.20%
Capital Research Global Investors1.70%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 2.0 points over the period — profitability is trending down.

Cash conversion4.54×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend9.0% → 6.9%

Margin has compressed by about 2.0 points over the period — profitability is trending down.

Return on equity128.7%

Latest ROE of 128.7% — capital is generating a healthy return.

Growth qualityrev 6% · PAT -7%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $18.3B · EPS 3.88

Est. earnings growth +43.3%

Next fiscal year

Rev $73.6B · EPS 16.21

Est. earnings growth +16.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$61.2B

Net margin

6.9%

Revenue CAGR (2y)

+6.1%

Profit CAGR (2y)

-6.8%

EPS (FY2025)

2.36

Net profit (FY2025)

$4.2B

Ask MarketChacha about ABBV

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about ABBV

Spyre's arthritis drug beat placebo — so why is SYRE down 14%?c/usmarkets · 8/26/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$61.2B	$4.2B	2.36	6.9%	—
FY2024	$56.3B	$4.3B	2.39	7.6%	128.7%
FY2023	$54.3B	$4.9B	2.72	9.0%	46.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$17.0B	$3.6B	2.03	21.3%
2026Q1	$15.0B	$695.0M	0.39	4.6%
2025Q4	$16.6B	$1.8B	1.02	10.9%
2025Q3	$15.8B	$186.0M	0.10	1.2%
2025Q2	$15.4B	$938.0M	0.52	6.1%
2025Q1	$13.3B	$1.3B	0.72	9.6%
2024Q4	$15.1B	$-22.0M	-0.02	-0.1%
2024Q3	$14.5B	$1.6B	0.88	10.8%
2024Q2	$14.5B	$1.4B	0.77	9.5%
2024Q1	$12.3B	$1.4B	0.77	11.1%
2023Q4	$14.3B	$822.0M	0.46	5.7%
2023Q3	$13.9B	$1.8B	1.00	12.8%
2023Q2	$13.9B	$2.0B	1.14	14.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure, Exhibits
SEC9/3/2026material
8-K — Other events, Exhibits
SEC8/18/2026material
8-K — Other events, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/3/2026
8-K — Results of operations, Exhibits
SEC7/31/2026material
8-K — Results of operations, Exhibits
SEC7/6/2026material
8-K — Reg FD disclosure, Exhibits
SEC6/22/2026material
8-K — Shareholder vote results
SEC5/12/2026material
10-Q filing
SEC5/8/2026
8-K — Results of operations, Exhibits
SEC4/29/2026material
8-K — Results of operations, Exhibits
SEC4/3/2026material
8-K — Other events, Exhibits
SEC3/4/2026material
8-K — Other events, Exhibits
SEC2/26/2026material
10-K filing
SEC2/20/2026
8-K — Results of operations, Exhibits
SEC2/4/2026material
8-K — Results of operations, Exhibits
SEC1/7/2026material

2025

10-Q filing
SEC11/4/2025
8-K — Results of operations, Exhibits
SEC10/31/2025material
8-K — Results of operations, Exhibits
SEC10/3/2025material
8-K — Reg FD disclosure, Exhibits
SEC9/11/2025material
10-Q filing
SEC8/4/2025
8-K — Results of operations, Exhibits
SEC7/31/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.